Pre-Negotiation Valuation

Ashley J. Stevens, D.Phil.(Oxon), CLP, RTTP

FOCUS IP GROUP, LLC

The Technology Transfer Process



FOCUS IP GROUP, LLC

Agenda

- Valuation vs. Pricing
- How value is extracted in a license
- Risk and Value
- Valuation Methodologies
  - Cost
  - Industry Standards – Comparables
  - Rules of Thumb
  - Equity

FOCUS IP GROUP, LLC

Valuation → Pricing

- Various techniques
- Different answers
- An opinion

- A negotiation
- One outcome
- A commitment

FOCUS IP GROUP, LLC

Valuation ➔ Pricing

- With a valuation basis
- You negotiate the bases

FOCUS IP GROUP, LLC

Valuation ➔ Pricing

- With a valuation basis
- Without a valuation basis

- You negotiate the bases
- You negotiate from emotion

FOCUS IP GROUP, LLC

When Is Technology Valued?

- Retrospectively
  - By litigators
  - Discovery to obtain all relevant information
  - Value established at a point in time
  - Adversarial -- outcome imposed judicially
- Prospectively
  - By deal makers
  - Asymmetry of information
    - University understands technology
    - Company knows the market
  - Value extracted over time
  - Must be win-win

FOCUS IP GROUP, LLC

What do we mean by a "Valuation"

- A written analysis of what we believe the value of a technology to be
- Prepared to:
  - Give it to the other side
  - Identify the sources of the data
  - Discuss the data
  - Modify based on discussions with the other side
    - Data
    - Valuation methodology used

FOCUS IP GROUP, LLC

What do we mean by a "License Valuation"

- Constructing the various financial elements of a proposed license
  - Upfront payments
  - Ongoing pre-commercial payments
    - Patent costs
    - Milestone payments
    - Annual Minimum Royalties
    - Research support
  - Sublicense income sharing
  - Manufacturing
  - Earned royalties or sales/profit sharing
- **i.e., the Term Sheet**

FOCUS IP GROUP, LLC

Risk

Types of Risk

- R&D risk
  - FDA risk
- Standards risk
- Manufacturability risk
- Marketing risk
- Competitive risk
- Legal risk
  - Patent risk

<u>Overall</u>

- I in 10,000 drug candidates makes it to FDA approval
- 1 in 3,000 raw ideas make it to market
- 1/3rd to 2/3rd of new product launches fail to recoup their investment

FOCUS IP GROUP, LLC

Value vs. Risk



FOCUS IP GROUP, LLC

A Fundamental Principle of License Valuation

- We probably shouldn't even **TRY** to get paid upfront in full
- Our job is to **EXTRACT** the value over time
  - Share in the growth in value

Example: Gatorade

- In 1963, Robert Cade of U. FL offered Stokely van Camp the rights* for $1 million
- Stokely van Camp declined
  - Said the test market would cost $1 million, paying Cade $1 million would double their financial risk
  - Offered to pay royalties
- To date, Stokely / Quaker / Pepsi have paid over $1 billion

* Rights consisted of patent applications, trade secret formula and **trademark**

FOCUS IP GROUP, LLC

The Basic Ways to Approach Valuation -- the Licensing Guy's Perspective

- Cost
- Rules of Thumb
- Industry Standards – Comparables
- Ranking/Rating
- Discounted Cash Flow
- Monte Carlo
- Auction
- Common sense
- Equity

FOCUS IP GROUP, LLC

Today

- Cost
- Rules of Thumb
- Industry Standards – Comparables
- Equity

FOCUS IP GROUP, LLC

Look Back -- Cost

Look Back -- Cost

- Cost to develop plus a return
- Is cost to develop relevant?
  - Would you want to or be able to sell a used lottery ticket for what you paid for it?
  - Wasn't the technology developed with a GRANT?
- Three areas where cost enters license negotiations:
  - For academic institutions
    - Sunk patent costs
    - Relative ownership in a collaboration

FOCUS IP GROUP, LLC

Cost Driven Negotiation



Source: Richard Razgaitis

Examples of Cost-Based Valuations

- U. of Minnesota and Penn State sponsored research models
  - Sponsor can get a fully paid up license for an extra 10% of the research costs
    - 10% of the **fully loaded** costs, including IDC
- Disease foundation funding model
  - Demand royalties in return for their funding
    - Royalties typically capped at 2x amount invested

FOCUS IP GROUP, LLC

Look to your Hand – Rules of Thumb

-- the 25% Rule

FOCUS IP GROUP, LLC

A Fundamental Principle of Technology Valuation

The Goldscheider Principle

(aka the 25% Rule)

"The Licensor should receive 25% and the Licensee should receive 75% of the pre-tax profits from a licensed product"

FOCUS IP GROUP, LLC

The 25% Rule

- Based on empirical observations
  - 18 worldwide licenses by Swiss subsidiary of US TV company PhilCo starting in 1959
  - Complete IP portfolio - patents, ongoing know-how, trademarks, copyrighted product materials
  - 3 year term, so readily renegotiable if terms inappropriate
  - Licensees made ~20% pre-tax profit, paid 5% royalty; were either #1 or #2 in their market despite strong competition
    - Happily renewed the licenses
  - Concluded that the licenses resulted in successful, long term win-win relationships
- Applied to fully-loaded pre-tax profits, not gross margin

FOCUS IP GROUP, LLC

Application

- Expressed as a % of net sales in license

  Royalty rate = 25% x expected profit margin
- Starting point for negotiation
- Limited value in academic licensing negotiations because of early stage
  - Very helpful when you're licensing to a new industry

FOCUS IP GROUP, LLC

Look Around – Industry Standards/Comparables

Comparable Transactions

- Probably the most important valuation method for academic licensing.
- Sources of Comparable Transactions
  - Internal database
  - Published surveys
  - Public announcements
  - Word of mouth
  - Litigation
  - Required disclosure

FOCUS IP GROUP, LLC

Internal Database

- Licenses previously done by your organization
- Trends over time

FOCUS IP GROUP, LLC

Published Surveys

- Relatively few in number
- Most are really old
- Three good recent surveys:
  - LES
    - BioPharmaceutical Royalty Rates and Deal Terms Survey (2008, 2009, 2012, 2014, 2016)
    - Chemicals, Energy, Environmental and Materials (CEEM) Survey (2010)
    - High Tech Survey (2011, 2014)

FOCUS IP GROUP, LLC

LES BioPharmaceutical Royalty Rates and Deal Terms Survey – 2016

- 165 responses, 117 complete and used
- Oncology, CNS and infectious diseases most prevalent
- 84% were exclusive
- 87% included U.S. and 80% were global
- 55% pre-IND
  - Very useful for universities
- 68% had expected peak sales <$500 million
- Royalty structure
  - 62% fixed royalties
  - 27% tiered royalties
  - 9% no royalty
    - 1% profit share
    - 8% no royalties

FOCUS IP GROUP, LLC

Flat Royalties
Average Royalty by Stage of Development

Royalty level increased with stage of development.



	Group 1	Group 2	Group 3	Group 4
No. of deals	27	6	5	7
Median	5%	5%	16%	15%
Min	1%	2%	3%	7%
Max	10%	20%	20%	30%

Flat vs. Tiered Royalties
Stage of Development

Within groups, mean flat royalty levels were below the values for tiered royalties.



AUTM

- TransACT
- Launched 2015
  - Academic deals
    - “Display to Pay”
      - Contribute a number of deals depending on your research volume
- Has severe limitations
  - The subject matter must be selected from a pick-list
    - All healthcare is the same code
      - E.g., a search for small molecule drugs yields ~80 hits
        - 26 have royalty rates
  - Can’t download all the data into a spreadsheet for analysis
    - One by one
- May be most useful for non-healthcare

FOCUS IP GROUP, LLC

Required Disclosure

- Contained in SEC filings
- Company must be public or have filed to go public
- Contained in **exhibits** to the S1 (IPO), 10K (Annual Report), 10Q (Quarterly Report) or 8K (Material Event)
- Only for “Material” transactions
  - 10% of sales, or
  - 5% of assets
- Can redact commercially sensitive information from public disclosure
  - Redaction has increased since transition to electronic filing
  - Redaction only good for 5 years
    - Some databases good at going back and getting the unredacted data

FOCUS IP GROUP, LLC

Steps

- Identify comparable transactions that would be helpful models
- Determine if the agreement has been filed with SEC
- Find it!

FOCUS IP GROUP, LLC

Accessing SEC Filings Yourself

- SEC EDGAR system
  - www.sec.gov/edgar/searchedgar/companysearch.html
  - Getting a lot more user friendly
  - Companies phased in progressively:
    - Largest January 1994
    - Smallest May 1996
  - For pre-Edgar transactions, early10K will show when/whether it was filed

FOCUS IP GROUP, LLC

Some Databases to Find Comparables

Technology	
RoyaltySource	royaltysource.com/
Tech Agreements	www.techagreements.com/
RoyaltyStat	www.royaltystat.com/
Business Valuation Resources	www.bvresources.com/

Life Sciences	
Clarivate (former ReCap)	www.cortellis.com/intelligence
BioScience Advisors	www.biosciadvisors.com
IQVIA (former PharmaDeals)	www.pharmadeals.net/
Strategic Transactions (Windhover)	www.elsevierbi.com/deals

- All charge – either per agreement ($35) or an annual subscription
- Some let you identify agreements before you have to pay
- Find them yourself through the SEC

Search Strategies

- No Cost
  - Search using TechAgreements (Physical Sciences) or Windhover (Life Sciences)
  - Find agreements using SEC
- High Cost Life Sciences
  - Search and get agreements using Clarivate or BioScience Advisors
- Alternative
  - Use a consultant for a specific technology
  - $2-3,000

FOCUS IP GROUP, LLC

Example

- siRNA
- Tools:
  - Clarivate
  - EDGAR

FOCUS IP GROUP, LLC

Cortellis

Clarivate Analytics

Home System Requirements Training About Us Site Search

CORTELLIS PLATFORM

You now need to log in using your email address in the Email Address field. This is not applicable if you access Cortellis via single-sign-on (SSO).

If you experience trouble logging in with your email address, please clear your che and cookies, close and re-open your browser and then log in

Sign in to continue with Cortellis

Email address
astevens@bu.edu

Password
••••••••••••••••

Forgot password? Sign in

Institution or company sign in (SSO)

r www.cortellis.com...

Type here to search





Deal Title	Principal Company	Principal Company Typ
Arcturus and Ultragenyx to discover and develop mRNA therapeutics using UNA	Arcturus Therapeutics Inc	Pharma
NCI to award PDX Pharmaceuticals funding for development of PDX-001 against breast	PDX Pharmaceuticals	Biotech
Regeneron and Alnylam to discover, develop and commercialize RNAi therapeutics for	Alnylam Pharmaceuticals Inc	Pharma
Janssen to develop and commercialize Arrowhead's ARO-HBV, with an option to	Arrowhead Pharmaceuticals Inc	Pharma
Nitto Denko and Osaka International Cancer Institute to develop new nucleic acid	Nitto Denko Corp	Other (non industrial)
Genzyme to develop Alnylam's RNAi therapeutics worldwide, excluding North	Alnylam Pharmaceuticals Inc	Pharma
Thea to develop and commercialize OliX's OLX-301A against age-related macular	OliX Pharmaceuticals Inc	Pharma
Karolinska Institute to conduct clinical trial fo Alnylam Pharmaceuticals' givosiran for acute	Karolinska Institutet	Academic
Medison Pharma to commercialize Alnylam's RNAi therapeutics for rare diseases in Israel	Alnylam Pharmaceuticals Inc	Pharma
Covance to provide OliX with GLP toxicology study services for OLX-10020 against GA	Covance Inc	Biotech
OliX Pharmaceuticals and University of Virginia School of Medicine to conduct	University of Virginia School of Medicine	Academic
Dicerna and Boehringer to discover and develop GalXC RNAi therapeutics for NASH	Dicerna Pharmaceuticals Inc	Pharma
Aro Biotherapeutics to develop and commercialize Janssen's Centyrin protein	Janssen Pharmaceuticals Inc	Pharma

Results

- 36 fields, covering:
  - Partners
  - Technology
  - Legal components of the deal
  - Financial terms
  - Actual documents
  - Stage of development

FOCUS IP GROUP, LLC

Results

- 548 deals
  - 109 had some financial information
  - 25 had royalty information
- 164 PSRI
  - 122 academic
  - 13 government agency
  - 29 non-profit
    - 41 had some financial information
    - 6 had royalty information, 1% - 10%
    - 6 had license agreement
      - 4 unredacted
      - 2 redacted

FOCUS IP GROUP, LLC

Results

Principal Company	Partner Company	Therapy Area	Indications	Drugs Status	Date	Total Value	Upfr.	Milest.	Royalty Rate (%)
Mayo Clinic	Alnylam	CNS	Parkinsons	Preclinical	10/01/03	3.97		3.75	1.00
Stanford	Alnylam	Unknown	Unidentified	Preclinical	09/17/03	0.77		0.73	2.00
U. of Penns.	Acuity	Ocular	AMD	Preclinical	03/31/03	1.00		0.95	2.00
U. of Illinois	Acuity	Ocular	Ocular	Discovery	08/01/06	2.50	0.03	2.45	3.00
UMass Med. Sch.	CytRx	Var,	Onc., NIDDM; Obesity	Discovery	04/15/03	6.50	0.08	6.3	10.00
UMass Med. Sch.	CytRx	CNS	ALS	Discovery	04/15/03	34.13	0.01	1.57	10.00

FOCUS IP GROUP, LLC

Old System

- A lot has been lost as the ReCap database has been repeatedly sold and reformatted
  - The unredacted copy of the agreement is available
    - Was in ReCap and Thomson Reuters versions
  - Only redacted version of the Acuity-U. of IL deal is available in Clarivate
  - Following is from the Thomson Reuters days
- I'm going to change my subscription to the new database created by Mark Edwards, BioScience Advisors
  - Creator of ReCap

FOCUS IP GROUP, LLC

Alliance Summary

R&D Company:	University of Illinois	**R&D Parent:**	
Client Company:	Acuity Pharmaceuticals	**Client Parent:**	Opko Health

Date: 08/2006
Parties: University / Biotech
Type: License
Subject:
TGF-B expression silencing by siRNA for ophthalmic diseases

Size:	$ 2.5 M	**Therapeutic Area:**	Ophthalmic Broad Focus Ophthalmic
Equity:	$ 0 M	**Technology:**	Gene Expression, Oligonucleotides - Ribozymes
Max. Royalty:	3 %	**Stage (at signing):**	Discovery

SNAPSHOT:



LICENSE

Exclusivity: Exclusive **Licensed Territory:** Worldwide

Contract Analysis

R&D Company:	University of Illinois	**R&D Parent:**	
Client Company:	Acuity Pharmaceuticals	**Client Parent:**	Opko Health
Agreement Date:	08/2006		
Alliance Summary:	Open parent Alliance Summary		

Related Contracts:

Agreement	Contract type	Contract date	pdf	Refile
University of Illinois / Acuity Pharmaceuticals (08/2006)	License	08/2006		

I. Research & Development

A. Scope of the Agreement
On 8/3/2006 ("Effective Date"), the University of Illinois (the "University") and Acuity Pharmaceuticals, Inc. ("Acuity") entered into a license agreement ("Agreement") to develop treatments for ophthalmic diseases based on TGF-beta receptor expression silencing by siRNA. [On 3/27/2007, Acuity and Froptix Corporation ("Froptix"), both privately owned, became Opko Health, Inc. ("Opko") through a reverse merger with publicly-traded eXegenics, Inc. (see Separate Deal Background -- Opko / Acuity, Froptix 3/07).]

B. Research Period
N/A

C. Cost Sharing & Reimbursement Basis
N/A

D. Upfront Payment
Acuity shall pay the University a $25K license fee within 3 business days of the Effective Date.

E. Benchmark Amounts
Acuity shall pay the University the following one-time milestone payments upon the first achievement of the following development milestone events: (1) $100K upon the initiation of phase I; (2) $350K upon the initiation of phase III; (3) $500K upon approval in the U.S.; and (4) $500K upon approval outside the U.S. Acuity shall pay the University a sales milestone of $1M upon reaching the first $25M in commercial sales of the Licensed Product (see Section II.A.).

F. Technology Acquisition Fees
N/A

G. Payment Schedule
N/A

H. Budgets
No

I. Reimbursement Start Date:
N/A

J. Regulatory Filings
All by Acuity.

K. Special Capital Requirements
None

L. Patent Ownership
The University shall not be obliged to provide Acuity or its sublicensees with any updates to the Technical Information. "Technology" shall mean the Inventions, Licensed Patents, and Technical Information, collectively. "Inventions" shall mean all devices, machines, methods, processes, manufactures, compositions of matter and uses, and Technical Information, contained in the disclosure entitled "CW081 Silencing of TGF-beta Receptor Expression by siRNA." "Licensed Patents" shall mean the following patents and applications owned by the University including any continuations, reissues, or foreign

Contract

R&D:	University of Illinois	**R&D Parent:**	
Client:	Acuity Pharmaceuticals	**Client Parent:**	Opko Health
Parties:	University / Biotech	**Subject:**	TGF-B expression silencing by siRNA for ophthalmic diseases
Alliance Summary:	Open parent Alliance Summary		

Alliance Type:	License	**Date:**	08/2006
		Revision:	

Contract Type:	License	**Filing Date:**	08/2006

CONTENT: EX-10.8 8 g06337exv10w8.htm EX-10.8 TECHNOLOGY LICENSE AGREEMENT

EXHIBIT 10.8

TECHNOLOGY LICENSE AGREEMENT

License Agreement ("**Agreement**"), effective as of August 3, 2006 between THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, (the "**University**"), and ACUITY PHARMACEUTICALS, INC., a Delaware corporation, having its principle place of business at 3701 Market Street, Philadelphia, PA, 19104 ("**Licensee**" or "**Acuity**").

Preliminary Statement

University holds certain rights to the Technology described below and desires to have the Technology commercialized. Licensee wishes to obtain the right to use the Technology for commercial purposes. Therefore, in consideration of the mutual obligations set forth below and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, University and Licensee agree as follows.

ARTICLE I
DEFINITIONS

The following capitalized terms are used in this Agreement with the following meanings:

1.1. "**Effective Date**" means August 3, 2006.

1.2. **"FDA"** means the United States Food and Drug Administration, or any successor thereto.

1.3. "**IND**" means an "investigational new drug application" as defined by the United States Food, Drug, and Cosmetic Act, as amended (the "Act"), and applicable FDA rules and regulations or a foreign equivalent.

1.4. **"Inventions"** means all devices, machines, methods, processes, manufactures, compositions of matter and uses, and Technical Information, contained in the disclosure entitled "CW081 Silencing of TGF ß Receptor Expression by SiRNA."

1.5. "**Licensed Field**" means the inhibition of and treatment of ophthalmic disease.

1.6. "**Licensed Patents**" means (a) the patents and patent applications listed on Schedule 1 and any continuations, divisionals, reissues, renewals, re-examinations, foreign counterparts, or substitutions of or to the above.

1.7. "**Licensed Product**" means any product or process or license for information, in the Field of Use, that is distributed by Licensee that is covered by any of the University's rights in the Technology.

1.8. **"NDA"** means a "new drug application," as defined in the Act and applicable FDA rules and regulations, including an application of the type described in section 505(b)(2) of the Act.

obligation to provide Licensee or any Sublicensee with any updates of or additional Technical Information owned, controlled or in the possession of any of them.

ARTICLE III
PAYMENTS

3.1. **Royalties and Reimbursements**. For the licenses granted in Section 2.1 of this Agreement, Licensee shall:

(a) within three (3) business days of the execution of this Agreement, pay University a non-refundable licensing fee in the amount of $25,000;

(b) within thirty (30) days of the first and second anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $25,000;

(c) within thirty (30) days of the third anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $50,000;

(d) within thirty (30) days of the fourth anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $50,000;

(e) within thirty (30) days of the fifth anniversary of the Effective Date and each subsequent anniversary thereafter until the Licensee receives NDA approval on its first Licensed Product, pay University an annual non-refundable licensing fee in the amount of $100,000;

(f) pay University a Royalty equal to three percent (3%) of Net Sales of Licensed Products sold, leased, rented, licensed or otherwise distributed by Licensee during the term of this Agreement, if any. If no valid claim of any issued patent among the Licensed Patents covers the Licensed Products in a country of the Territory, then the royalties shall be reduced to one and one-half percent (1.5%) of Net Sales of Licensed Products sold, leased, rented, licensed or otherwise distributed by Licensee in such country of the Territory.

3.2. **Milestones and Milestone Payments**. Licensee agrees to make the milestone payments to University as set forth below (the "**Milestone Payments**") within forty-five (45) days after the occurrence of each event set forth on such Schedule.

Milestone		**Payment**
First Phase I Clinical Trial initiated	$	100,000
First Phase III Clinical Trial initiated	$	350,000
First NDA Approval in the U.S	$	500,000
First NDA Equivalent Approval outside of US	$	500,000
Upon first $25,000,000 of commercial sales of any Licensed Products	$	1,000,000

Each of the foregoing payments shall be made only once. Thereafter, no additional Milestone Payments shall be due or payable by Licensee for License Products.

3.3. **Calculations and Payment of Royalties.**

(a) Royalties shall be paid in quarterly increments (the "Royalty Period"). Royalties shall be calculated for each Royalty Period as of the last day of each such Royalty Period. Payment of Royalties with respect to each Royalty Period shall be due within sixty (60) days after the end of Royalty Period, beginning with the earlier of (i) the Royalty Period in which the first sale of a Licensed Product occurs, or (ii) the Royalty Period for which Annual Minimum Royalties are due.

(b) Within sixty (60) days of the end of each Royalty Period (whether or not Royalties are due), Licensee shall deliver to University a true and complete accounting of sales or distributions of any Licensed Product and revenues from those sales by Licensee and its Sublicensees for each country of sales origin during such Royalty Period and deductions taken, with a separate accounting for each Licensed Product of sales and receipts by country, and a detailed calculation of the Royalty payment due University for such Royalty Period, in each case in form and

Search Results

Save Search Modify Search New Search

8 results.
CRITERIA: ([Company] CONTAINS "Acuity Pharmaceuticals")

	Parties	Date	Type	Size	Upfront	Total Milestone	Royalty	Subject
1	Acuity Pharmaceuticals, Froptix / Opko Health	03/2007	Acq, Mrg					Reverse merger with eXegenics to form Opko Health
2	University of Illinois / Acuity Pharmaceuticals	08/2006	L	$2.5	$0.0	$1.5	3.0%	TGF-B silencing by siRNA for ophthalmic diseases
3	ZaBeCor / Acuity Pharmaceuticals	04/2006	L, O					Excellair anti-Inflammatory siRNA for Ophthamalic uses
4	Pathogenics / Acuity Pharmaceuticals	04/2006	L	$6.5	$0.1	$6.4	6.0%	N-chlorotaurine For Ophthalmic Use
5	Intradigm / Acuity Pharmaceuticals	06/2005	CoD, Col, L, E	$5.6	$0.5	$5.1	8.0%	siRNA for topical delivery to the eye
6	Ocimum Biosolutions / Acuity Pharmaceuticals	08/2004	L					Genchek-Comprehensive Sequence Analysis Tool
7	University of Pennsylvania / Acuity Pharmaceuticals	03/2003	L, E	$1.0		$1.0	8.0%	RNA interference technologies (Gewirtz)
8	University of Pennsylvania / Acuity Pharmaceuticals	03/2003	L, E	$1.0		$1.0	2.0%	RNA interference technologies (Reich/Tolentinio)

U.S. SECURITIES AND EXCHANGE COMMISSION

Searc

COMPANY FILIN

ABOUT | DIVISIONS | ENFORCEMENT | REGULATION | EDUCATION | FILINGS | NEWS

- EDGAR Search Tools
- Latest Filings
- Company Filings
- Mutual Funds
- Variable Insurance Products
- Daily Filings by Type
- Boolean Archive Search
- Full Text (Past 4 Years)
- CIK Lookup
- Confidential Treatment Orders

EDGAR | Company Filings

Free access to more than 21 million filings

We're improving EDGAR. Prefer th

Company Name

Opko SEARCH

More Options

Fast Search

Ticker or CIK

Ticker symbol or CIK company filings.

Guides

How to Research Public Companies

Learn how to quickly research a company's operations and financial information with EDGAR search tools.

Form Types

Review reference versions of EDGAR forms filed by companies, funds, and individuals.

Search Tools

CIK Lookup Tool

Look up the central index key (CI Searching by CIK is the most acc filings.

Save Your Search

Want to get updates on new filing your search by subscribing to ED

EDGAR Search Results

SEC Home » Search the Next-Generation EDGAR System » Company Search » *Current Page*

Opko Health, Inc. CIK#: 0000944809 (see all company filings)

SIC: 2834 - PHARMACEUTICAL PREPARATIONS
State location: FL | State of Inc.: **DE** | Fiscal Year End: 1231
formerly: CYTOCLONAL PHARMACEUTICS INC /DE (filings through 2001-06-04)
formerly: EXEGENICS INC (filings through 2007-06-13)
formerly: eXegenics Inc (filings through 2007-06-13)
(Assistant Director Office: 1)
Get **insider transactions** for this **issuer**.
Get **insider transactions** for this **reporting owner**.

Business
4400 BISC
MIAMI FL
305-575-4

Filter Results: Filing Type: 8-K Prior to: (YYYYMMDD) Ownership? include / exclude / only

Items 1 - 40 RSS Feed

Filings	Format	Description
8-K	Documents	Current report, item 5.02 Acc-no: 0000944809-19-000043 (34 Act) Size: 37 KB
8-K	Documents	Current report, items 5.03, 5.07, 7.01, and 9.01 Acc-no: 0000944809-19-000041 (34 Act) Size: 89 KB
SC 13D	Documents	General statement of acquisition of beneficial ownership Acc-no: 0001193125-19-171306 Size: 124 KB
SC 13D	Documents	General statement of acquisition of beneficial ownership Acc-no: 0001193125-19-171303 Size: 117 KB
SC 13D	Documents	General statement of acquisition of beneficial ownership Acc-no: 0001193125-19-171298 Size: 113 KB
SC 13D	Documents	General statement of acquisition of beneficial ownership Acc-no: 0001193125-19-171297 Size: 116 KB
8-K	Documents	Current report, item 7.01 Acc-no: 0000944809-19-000039 (34 Act) Size: 30 KB
8-K	Documents	Current report, item 8.01 Acc-no: 0000944809-19-000036 (34 Act) Size: 28 KB

U.S. Securities

EDGAR Search Results

SEC Home » Search the Next-Generation EDGAR System » Company Search » *Current Page*

Opko Health, Inc. CIK#: 0000944809 (see all company filings)

SIC: 2834 - PHARMACEUTICAL PREPARATIONS
State location: FL | State of Inc.: **DE** | Fiscal Year End: 1231
formerly: CYTOCLONAL PHARMACEUTICS INC /DE (filings through 2001-06-04)
formerly: EXEGENICS INC (filings through 2007-06-13)
formerly: eXegenics Inc (filings through 2007-06-13)
(Assistant Director Office: 1)
Get **insider transactions** for this **issuer**.
Get **insider transactions** for this **reporting owner**.

Business Address
4400 BISCAYNE BLVD.
MIAMI FL 33137
305-575-4138

Ma
44
MI

Filter Results: Filing Type: 8-K | Prior to: (YYYYMMDD) 2008/01/01 | Ownership? include exclude only | Limit Results Per Page 40 Entries

Items 1 - 40 RSS Feed

Filings	Format	Description	Filing Date
8-K	Documents	Current report, items 1.01, 3.02, and 9.01 Acc-no: 0001144204-07-065847 (34 Act) Size: 52 KB	2007-12-05
8-K	Documents	Current report, items 1.01, 2.01, and 9.01 Acc-no: 0001144204-07-064922 (34 Act) Size: 49 KB	2007-11-29
8-K	Documents	Current report, items 5.02 and 8.01 Acc-no: 0000950144-07-008821 (34 Act) Size: 12 KB	2007-09-25
8-K	Documents	Current report, items 1.01, 5.02, and 9.01 Acc-no: 0000950144-07-004724 (34 Act) Size: 66 KB	2007-05-11
8-K	Documents	Current report, item 1.01 Acc-no: 0000950144-07-003524 (34 Act) Size: 11 KB	2007-04-18
8-K	Documents	Current report, items 4.01, 5.02, and 9.01 Acc-no: 0000950144-07-003401 (34 Act) Size: 47 KB	2007-04-13
8-K	Documents	Current report, items 1.01, 2.01, 3.02, 5.01, 5.02, 5.06, and 9.01 Acc-no: 0000950144-07-002945 (34 Act) Size: 2 MB	2007-04-02
8-K	Documents	Current report, items 3.03 and 9.01 Acc-no: 0001144204-07-014826 (34 Act) Size: 44 KB	
8-K	Documents	Current report, items 3.02, 5.01, 5.02, 8.01, and 9.01	2007-02-09

Form 8-K - *Current report:*

Filing Date
2007-04-02
Accepted
2007-04-02 07:13:22
Documents
22

Period of Report
2007-03-27

Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.02: Unregistered Sales of Equity Securities
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.06: Change in Shell Company Status
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq	Description	Document	Type	Size
1	EXEGENICS, INC.	g06337e8vk.htm	8-K	889948
2	EX-2.1 MERGER AGREEMENT & PLAN OF REORGANIZATION	g06337exv2w1.htm	EX-2.1	294509
3	EX-4.1 FORM OF COMMON STOCK WARRANT	g06337exv4w1.htm	EX-4.1	33331
4	EX-4.2 FORM OF SERIES C PREFERRED STOCK WARRANT	g06337exv4w2.htm	EX-4.2	32645
5	EX-10.1 FORM OF LOCK-UP AGREEMENT	g06337exv10w1.htm	EX-10.1	9947
6	EX-10.2 CREDIT AGREEMENT	g06337exv10w2.htm	EX-10.2	86185
7	EX-10.3 AMENDED & RESTATED VENTURE LOAN AGREEMENT	g06337exv10w3.htm	EX-10.3	210041
8	EX-10.8 TECHNOLOGY LICENSE AGREEMENT	g06337exv10w8.htm	EX-10.8	96413
9	EX-10.9 LICENSE AGREEMENT	g06337exv10w9.htm	EX-10.9	87487
10	EX-10.10 AMENDMENT NO. 1 TO LICENSE AGREEMENT	g06337exv10w10.htm	EX-10.10	8079
11	EX-10.11 AMENDMENT NO. 2 TO LICENSE AGREEMENT	g06337exv10w11.htm	EX-10.11	7548
12	EX-10.12 LICENSE AND COLLABORATION AGREEMENT	g06337exv10w12.htm	EX-10.12	127884
13	EX-10.13 UNIV. OF PENN. LICENSE AGREEMENT	g06337exv10w13.htm	EX-10.13	66692
14	EX-10.14 UNIV. OF PENN LICENSE AGREEMENT	g06337exv10w14.htm	EX-10.14	66493
15	EX-10.15 1ST AMENDMENT TO UPENN LICENSE AGREEMENT	g06337exv10w15.htm	EX-10.15	12050
16	EX-10.16 1ST AMENDMENT TO UPENN LICENSE AGREEMENT	g06337exv10w16.htm	EX-10.16	10147
17	EX-10.17 AMENDED RESTATED SUBORDINATION AGREEMENT	g06337exv10w17.htm	EX-10.17	25982
18	EX-10.18 REICH EMPLOYMENT LETTER	g06337exv10w18.htm	EX-10.18	25379
19	EX-10.19 PFOST EMPLOYMENT AGREEMENT	g06337exv10w19.htm	EX-10.19	51353
20	EX-99.1 PRESS RELEASE	g06337exv99w1.htm	EX-99.1	9676
21	GRAPHIC	g06337g0633701.gif	GRAPHIC	7428
22	GRAPHIC	g06337g0633702.gif	GRAPHIC	1541
	Complete submission text file	0000950144-07-002945.txt		216658

eXegenics Inc (Filer) CIK: 0000944809 (see all company filings)

IRS No.: **752402409** | State of Incorp.: **DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-26648** | Film No.: **07735592**

Business Address
1250 PITTSFORD-VICTOR ROAD
BUILDING 200, SUITE 280

EXHIBIT 10.8

TECHNOLOGY LICENSE AGREEMENT

License Agreement ("**Agreement**"), effective as of August 3, 2006 between THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, (the "**University**"), and ACUITY PHARMACEUTICALS, INC., a Delaware corporation, having its principle place of business at 3701 Market Street, Philadelphia, PA, 19104 ("**Licensee**" or "**Acuity**").

Preliminary Statement

University holds certain rights to the Technology described below and desires to have the Technology commercialized. Licensee wishes to obtain the right to use the Technology for commercial purposes. Therefore, in consideration of the mutual obligations set forth below and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, University and Licensee agree as follows.

ARTICLE I
DEFINITIONS

The following capitalized terms are used in this Agreement with the following meanings:

1.1. "**Effective Date**" means August 3, 2006.

1.2. **"FDA"** means the United States Food and Drug Administration, or any successor thereto.

1.3. "**IND**" means an "investigational new drug application" as defined by the United States Food, Drug, and Cosmetic Act, as amended (the "Act"), and applicable FDA rules and regulations or a foreign equivalent.

1.4. **"Inventions"** means all devices, machines, methods, processes, manufactures, compositions of matter and uses, and Technical Information, contained in the disclosure entitled "CW081 Silencing of TGF ß Receptor Expression by SiRNA."

1.5. "**Licensed Field**" means the inhibition of and treatment of ophthalmic disease.

1.6. "**Licensed Patents**" means (a) the patents and patent applications listed on Schedule 1 and any continuations, divisionals, reissues, renewals, re-examinations, foreign counterparts, or substitutions of or to the above.

1.7. "**Licensed Product**" means any product or process or license for information, in the Field of Use, that is distributed by Licensee that is covered by any of the University's rights in the Technology.

1.8. **"NDA"** means a "new drug application," as defined in the Act and applicable FDA rules and regulations, including an application of the type described in section 505(b)(2) of the Act.

1.9. "**Net Sales**" means the total gross proceeds to Licensee on sales and any other distributions of Licensed Products to third parties, less deductions for the following to the extent actually paid with respect to such sales or distributions:

(a) Customary rebates;

3.1. **Royalties and Reimbursements**. For the licenses granted in Section 2.1 of this Agreement, Licensee shall:

(a) within three (3) business days of the execution of this Agreement, pay University a non-refundable licensing fee in the amount of $25,000;

(b) within thirty (30) days of the first and second anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $25,000;

(c) within thirty (30) days of the third anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $50,000;

(d) within thirty (30) days of the fourth anniversary of the Effective Date, pay University a non-refundable licensing fee in the amount of $50,000;

(e) within thirty (30) days of the fifth anniversary of the Effective Date and each subsequent anniversary thereafter until the Licensee receives NDA approval on its first Licensed Product, pay University an annual non-refundable licensing fee in the amount of $100,000;

(f) pay University a Royalty equal to three percent (3%) of Net Sales of Licensed Products sold, leased, rented, licensed or otherwise distributed by Licensee during the term of this Agreement, if any. If no valid claim of any issued patent among the Licensed Patents covers the Licensed Products in a country of the Territory, then the royalties shall be reduced to one and one-half percent (1.5%) of Net Sales of Licensed Products sold, leased, rented, licensed or otherwise distributed by Licensee in such country of the Territory.

3.2. **Milestones and Milestone Payments**. Licensee agrees to make the milestone payments to University as set forth below (the "**Milestone Payments**") within forty-five (45) days after the occurrence of each event set forth on such Schedule.

Milestone	Payment
First Phase I Clinical Trial initiated	$ 100,000
First Phase III Clinical Trial initiated	$ 350,000
First NDA Approval in the U.S	$ 500,000
First NDA Equivalent Approval outside of US	$ 500,000
Upon first $25,000,000 of commercial sales of any Licensed Products	$1,000,000

Each of the foregoing payments shall be made only once. Thereafter, no additional Milestone Payments shall be due or payable by Licensee for License Products.

3.3. **Calculations and Payment of Royalties.**

(a) Royalties shall be paid in quarterly increments (the "Royalty Period"). Royalties shall be calculated for each Royalty Period as of the last day of each such Royalty Period. Payment of Royalties with respect to each Royalty Period shall be due within sixty (60) days after the end of Royalty Period, beginning with the earlier of (i) the Royalty Period in which the first sale of a Licensed Product occurs, or (ii) the Royalty Period for which Annual Minimum Royalties are due.

(b) Within sixty (60) days of the end of each Royalty Period (whether or not Royalties are due), Licensee shall deliver to University a true and complete accounting of sales or distributions of any Licensed Product and revenues from those sales by Licensee and its Sublicensees for each country of sales origin during such Royalty Period and deductions taken, with a separate accounting for each Licensed Product of sales and receipts by country, and a detailed calculation of the Royalty payment due University for such Royalty Period, in each case in form and substance as set forth on Exhibit A attached to this Agreement. If no sales of Licensed Products were made or other payments due in such Royalty Period, then Licensee's statement shall so state.

(c) Each Annual Minimum Royalty payment shall be accompanied by a calculation of the Annual Minimum Royalty such that University can verify the amount of the payment.

3.4. **Royalty stacking and combination products**: The royalty rate will not diminish for combination products or stacking royalties.

3.5. **Annual Minimum Payments**. Beginning one year after the Licensee or any Sublicensee receives NDA approval on its first Licensed Product, it the total payments actually paid to University payments (including any payments

Company Valuation

- Most recent 10Q to get number of shares outstanding
- Share prices:
  - www.nasdaq.com/

FOCUS IP GROUP, LLC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended March 31, 2019.

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____.

Commission file number 001-33528

OPKO Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	75-2402409
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

4400 Biscayne Blvd.
Miami, FL 33137
(Address of Principal Executive Offices) (Zip Code)

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES ☐ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ YES ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company"
(in Rule 12b-2 of the Exchange Act) (Check one):

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐
		Emerging growth company	☐

Table of Contents

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): ☐ YES ☒ NO

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock	OPK	NASDAQ Global Select Market

As of April 24, 2019, the registrant had 615,601,045 shares of Common Stock outstanding.

Table of Contents

U.S. Stock Quotes, Charts, and Research

Find stock quotes, interactive charts, historical information, company news and stock analysis on all public companies in the U.S..

1 Get A Stock Quote: Enter up to 25 symbols

Symbol Lookup | New to Quotes? Check out our Frequently Asked Questions

Opko

2 Click a link below to filter your results

Quotes
- Real-time Quotes
- Flash Quotes
- InfoQuotes
- Summary Quotes
- After Hours Quotes
- Pre-Market Quotes
- NLS Trade Reporting
- Options Trading Center
- Historical Quotes

Charts
- Basic Charts
- Comparison Charts
- Interactive Charts

Companies
- Company News
- Press Releases
- Market Stream
- Nasdaq Companies
- Companies by Region

Stock Analysis
- Analyst Research

Fundamentals
- Financials

Holdings/Ownership
- Ownership Summary

ADDITIONAL STOCK RESEARCH

View Security List	Download Security List
NASDAQ	NASDAQ (406KB)
Amex	Amex (51KB)
NYSE	NYSE (412KB)

U.S. Symbol Changes

OPKO Health, Inc. Common Stock (OPK) Quote & Summary Data

OPK $2.37* **0.04 ↓ 1.66%**

*Delayed - data as of Jul. 3, 2019 - Find a broker to begin trading OPK now

Exchange: NASDAQ
Industry: Health Care
Community Rating: Bullish

Edit Symbol List
Symbol Lookup

OPK | SGMO | CLLS | S | CRSP | EDIT | NTLA | NDAQ

Save Stocks | Refresh

SYMBOL LIST VIEWS
FlashQuotes
InfoQuotes
STOCK DETAILS
Summary Quote
Real-Time Quote
After Hours Quote
Pre-market Quote
Historical Quote
Option Chain
CHARTS
Basic Chart
Interactive Chart
COMPANY NEWS
Company Headlines
Press Releases
Market Stream
STOCK ANALYSIS
Analyst Research
Guru Analysis
Stock Report

Key Stock Data

Best Bid / Ask	N/A / N/A	P/E Ratio	NE
1 Year Target	4.5	Forward P/E (1y)	NE
Today's High / Low	$ 2.41 / $ 2.33	Earnings Per Share (EPS)	$ -0.33
Share Volume	2,370,522	Annualized Dividend	N/A
50 Day Avg. Daily Volume	4,944,550	Ex Dividend Date	N/A
Previous Close	$ 2.41	Dividend Payment Date	N/A
52 Week High / Low	$ 6.40 / $ 1.73	Current Yield	0 %
Market Cap	1,458,974,477	Beta	2.52

Intraday Chart

1D | 5D | 1m | 3m | 6m | 1y

More OPK Charting >

Upcoming Earnin

Company	Expect
FGP	Jun 10,
THO	Jun 10,
HDS	Jun 11,
HRB	Jun 11,
CHS	Jun 11,
AVGO	Jun 13,
TUFN	Jun 13,
CPST	Jun 11,

See Also

1 | Best Stocks To
2 | IPO Investment
3 | #1 Penny Stock
4 | Ipo Stocks To W

CONSENSUS RE

OPK $2.37* 0.04 ↓ 1.66%

*Delayed - data as of Jul. 3, 2019 - Find a broker to begin trading OPK now

Community Rating: Bullish

Edit Symbol List
Symbol Lookup

OPK | SGMO | CLLS | S | CRSP | EDIT | NTLA | NDAQ

Save Stocks

SYMBOL LIST VIEWS
FlashQuotes
InfoQuotes
STOCK DETAILS
Summary Quote
Real-Time Quote
After Hours Quote
Pre-market Quote
Historical Quote
Option Chain
CHARTS
Basic Chart
Interactive Chart
COMPANY NEWS
Company Headlines
Press Releases
Market Stream
STOCK ANALYSIS
Analyst Research
Guru Analysis
Stock Report
Competitors
Stock Consultant
Stock Comparison
FUNDAMENTALS
Call Transcripts



The chart comes up showing a I year history. Pick 10 years and hit “Go”.

Time Frame: 1 Year

Chart Display:

Chart Type:
OHLC | Bar | Line | Candlestick | Mountain

Indicators:
Splits | Earnings *

Moving Average:
None | 20 Day | 50 Day | 200 Day

Lower Studies:

OPK $2.37* 0.04 ↓ 1.66%

*Delayed - data as of Jul. 3, 2019 - Find a broker to begin trading OPK now

Community Rating: Bullish

Edit Symbol List
Symbol Lookup

OPK | SGMO | CLLS | S | CRSP | EDIT | NTLA | NDAQ

Save Stocks

SYMBOL LIST VIEWS
FlashQuotes
InfoQuotes
STOCK DETAILS
Summary Quote
Real-Time Quote
After Hours Quote
Pre-market Quote
Historical Quote
Option Chain
CHARTS
Basic Chart
Interactive Chart
COMPANY NEWS
Company Headlines
Press Releases
Market Stream
STOCK ANALYSIS
Analyst Research
Guru Analysis
Stock Report
Competitors
Stock Consultant
Stock Comparison
FUNDAMENTALS
Call Transcripts

Time Frame: 10 Years

Chart Display:

Chart Type:
○ OHLC ○ Bar ○ Line ○ Candlestick ◉ Mountain

Indicators:
☑ Splits ☑ Earnings *

Moving Average:
◉ None ○ 20 Day ○ 50 Day ○ 200 Day

Lower Studies:

$2.37 x 615,601,045 shares = $1,458,974,476

If U. of IL still owned 3%, worth $43,769,234

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- Companies seem to be making much more detailed disclosures of deal terms in their 10-K's these days
  - 10-K's are much easier to find and search than attached agreements
- Example
  - Asian university developing a cellular therapy
  - Model: CAR-T's
    - Leading U.S. companies
      - Juno Therapeutics
        - Five academic stage deal terms identified

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- Companies seem to be making much more detailed disclosures of deal terms in their 10-K's these days
  - 10-K's are much easier to find and search than attached agreements
- Example
  - Asian university developing a cellular therapy
  - Model: CAR-T's
    - Leading U.S. companies
      - Juno Therapeutics
        - Five academic stage deal terms identified

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- Fred Hutchinson Cancer Center
  - Upfront payment of $250,000;
  - An annual maintenance fee of $50,000 for the first four years thereafter minimum annual royalties of $100,000 per year;
  - With respect to JCAR014 and JCAR017, milestone payments of $6.75 million per licensed product
  - Low single-digit royalties
    - i.e., 3-4%
  - A portion of the payments from sublicensees, on a tiered basis, up to a cap.

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- Memorial Sloan-Kettering Cancer Center
  - Upfront payment of $6.9 million;
  - Annual minimum royalties of $100,000 commencing of the fifth anniversary of the agreement;
  - Mid-to-high single-digit royalties on annual net sales of licensed products or the performance of licensed services by us and our affiliates and sublicensees
    - i.e., 5-9%;
  - $6.75 million in clinical and regulatory milestone payments for each licensed product including JCAR015

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- Seattle Children's Research Institute
  - Upfront payment of $200,000;
  - Annual license maintenance fees of $50,000 per year for the first five years and $200,000 per year thereafter;
  - Low single-digit royalties based on annual net sales of licensed products and licensed services by us and our affiliates and sublicensees
    - i.e., 2-4%
  - For ***JCAR014 and JCAR017***, milestone payments totaling up to $13.3 million and up to $3.0 million in commercial milestone payments;
  - A percentage of sublicensee payments up to an aggregate of $15.0 million
- **Additive to Fred Hutchinson**

FOCUS IP GROUP, LLC

A Newer Way to Use SEC Filings

- St. Jude's Children's Research Hospital
  - An upfront payment of $25.0 million;
  - Low single-digit royalties
    - i.e., 2-4%
  - $100,000 minimum annual royalty for the first two years of the agreement, and a $500,000 minimum royalty thereafter
  - Milestone payments of up to an aggregate of $62.5 million for ***JCAR014 and JCAR017***
  - A percentage of sublicense income and settlement payments.
- **Also additive to Fred Hutchinson**

FOCUS IP GROUP, LLC

Juno vs Kite

- Juno and Memorial Sloan-Kettering sued Kite over Yescarta® in October 2017
  - 7,446,190
    - Expires May 2023
  - Kite bought by Gilead for $11.9 billion in August 2017
  - Juno bought by Celgene for $9 billion in January 2018
    - Celgene bought by BMS for $74 billion in January 2019
- Yescarta ® approved October 2017
  - Relapsed / refractory large B-cell lymphoma
    - 2019 sales $489 million
    - 2022 forecast $1.47 billion
- BMS awarded $752 million in damages in December 2019

FOCUS IP GROUP, LLC

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819

FOCUS IP GROUP, LLC

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819
Royalties	7.0%	$ 1	$ 18	$34	$53	$77	$103	$57

FOCUS IP GROUP, LLC

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819
Royalties	7.0%	$ 1	$ 18	$34	$53	$77	$103	$57
Discount rate	11%	1.23	1.11	1	0.90	0.81	0.73	0.66

FOCUS IP GROUP, LLC

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819
Royalties	7.0%	$ 1	$ 18	$34	$53	$77	$103	$57
Discount rate	11%	1.23	1.11	1	0.90	0.81	0.73	0.66
Discounted royalties		$1.72	$20.51	$34.23	$47.30	$62.49	$75.24	$37.74
Total								$279.24

FOCUS IP GROUP, LLC

Yescarta®

		2017	2018	2019	2020	2021	2022	2023
Sales		$20	$264	$489	$750	$1,100	$1,470	$819
Royalties	18.9%	$4	$50	$92	$141	$207	$277	$154
Discount rate	11%	1.23	1.11	1	0.90	0.81	0.73	0.66
Discounted royalties		$4.65	$55.24	$92.18	$27.37	$168.30	$202.62	$101.64
Total								$752.00

FOCUS IP GROUP, LLC

Reconciliation

- Juno-MSK License 5-9%
- Litigation 18.9%

- Reasons:
  1. In litigation, patent is presumed valid and infringed
     - In licensing, uncertainty as to validity
  2. In litigation, royalty is determined on the eve of infringement
     - Later of patent issuance and product launch
       - License is done at much earlier stage
       - Royalty rates for marketed products much higher than for preclinical / Phase 1 products

FOCUS IP GROUP, LLC

Equity

Equity

- Extract value by licensing to a start-up
- In most countries, university gets an ownership stake
  - Instead of an upfront fee
  - Normal other royalty terms
    - Milestones, annual minimums, running royalties, etc.
- Because of fairness / corruption concerns in some emerging countries, we are proposing a standard formula for the distribution of initial equity

FOCUS IP GROUP, LLC

Equity – Dividing up the Pie

Inventor – 25%
- Gets to spend 1 day per week

Investors – 25%
- For $50,000 investment
- Values company at $200,000



University – 25%
- Part of license consideration
- Compensate for professor's time
- Provide office for 1 year

Management Team – 25%

FOCUS IP GROUP, LLC

Equity – Dividing up the Pie

50% to the private sector



50% to the university

Basis

- U.K. model:
  - Even split between professor and university:
- Columbia University model
  - Standard equity model for every start-up
    - For all sectors
    - Royalty terms vary by sector
      - Higher for software and pharmaceuticals
      - Lower for engineering, manufacturing
        - Depends on profitability

Equity – How the Pie Changes

- As more investors are brought in, more shares issued
  - Everyone gets diluted
- As more employees are brought in, more shares are issued
  - Everyone gets diluted some more

FOCUS IP GROUP, LLC

And if all else fails……..

5%

Valuation

THIS INDENTURE made this 30th day of May, A.D.

1922

BETWEEN

The Governors of the University of Toronto,

of the First Part;

-and-

The Eli Lilly Company, Incorporated under the laws of the State of Indiana, of Indianapolis, in Marion County and State of Indiana.

of the Second Part.

WHEREAS the Party of the First Part is the owner of a pancreatic extract or product for the treatment of diabetes mellitus and a process for preparing the same for which application for Letters Patent was filed in the United States Patent Office on or about the 22nd day of May, A. D. 1922 under Serial Number 562, 835.

AND WHEREAS the party of the First Part is not in a

Patent granted for the said process and product and any improvements thereto, on the same favourable terms as other firms similarly licensed by the said party of the first part and the said party of the second part in consideration of the said licence shall pay to the party of the first part a royalty of 5% of the net selling prices which the said party of the second part receives for the product, during the life of such patent.

(10) In the event of the said party of the second part, during the said experimental period or subsequently during the period of the license referred to in paragraph 9, shall develop, improve, or simplify methods of producing the said pancreatic extract, full and complete information regarding such methods shall be communicated by the party of the second part to the said party of the first part for use in the preparation of the said extract.

List Pricing

- As you get more familiar with tech transfer and do more deals, you'll have a good feel for what they're worth
  - Won't need to go through a specific valuation exercise for each one

For More Information

- Intellectual Property Valuation Manual For Academic Institutions
  - Ashley J. Stevens
  - World Intellectual Property Organization (WIPO), Geneva, Switzerland, March 2016,
  - Available at: http://www.wipo.int/meetings/en/doc_details.jsp?doc_id=332588

FOCUS IP GROUP, LLC

Thank you for listening.

Questions?

astevens@bu.edu

FOCUS IP GROUP, LLC